Australia markets closed

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.29+0.04 (+0.55%)
At close: 04:00PM EDT
7.30 +0.01 (+0.14%)
After hours: 04:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.25
Open7.25
Bid0.00 x 1000
Ask0.00 x 800
Day's range7.06 - 7.41
52-week range6.09 - 37.17
Volume235,934
Avg. volume277,524
Market cap285.587M
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-4.00
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est39.60
  • GlobeNewswire

    Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

    Erosive Esophagitis (EE) New Drug Application (NDA) accepted by U.S. Food and Drug Administration (FDA) with Prescription Drug User Fee Act (PDUFA) action date of January 11, 2023; if approved, targeting U.S. launch in Q1 2023 VOQUEZNA DUAL and TRIPLE PAK approved by FDA for treatment of H. pylori infection on May 3, 2022 Initial testing for nitrosamines revealed trace levels in vonoprazan commercial drug product; working with FDA to make VOQUEZNA DUAL and TRIPLE PAK available to patients as soo

  • GlobeNewswire

    Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

    FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET. Company management will also participate in one-on-one meetings during the conference which runs

  • GlobeNewswire

    Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

    FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for vonoprazan as a treatment for adults for the healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all